Letter to the Editor: Claims about the effects of botulinum toxin on depression should raise some eyebrows.
Recently, Schulze and colleagues (2021) and we (Coles, Larsen, Kuribayashi, & Kuelz, 2019) published two separate meta-analyses examining whether glabellar-region botulinum toxin injections can decrease depression. Both meta-analysis teams reviewed similar studies; discussed similar mechanisms-of-action; observed unexpectedly large effect sizes; observed asymmetry in funnel plot distributions; and acknowledged that it is difficult to blind participants. Yet, our two teams came to starkly different conclusions. Whereas Schulze and colleagues concluded that the treatment reaches rigorous “1a level of evidence” standards (p. 338), we concluded the opposite: that the claim is “not yet well substantiated by a credible balance of evidence” (p. 11). In this Letter to the Editor, we clarify why we believe that a more careful consideration of the quality of the evidence, potential costs, and potential benefits is necessary before promoting botulinum toxin as an off-label treatment for depression.